Application of Falnidamol in reversing multidrug resistance of tumor

• Main Authors: FENG WEIGUO, PAN ZHIFANG, ZHANG MENG, LIU BAOJIE, LU YONGZHENG
• Format: Patent
• Language: Chinese; English
• Published: 28.05.2024
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention belongs to the technical field of biological medicines, and relates to treatment of multidrug resistance tumors, in particular to application of falnidamol in reversing multidrug resistance of tumors. Research finds that the falnidamol serving as an efficient ABCB1 protein inhibitor can inhibit the chemotherapeutic drug excretion function of the ABCB1 protein through interaction with a substrate binding site of the ABCB1 protein, increase the drug concentration in cells, effectively reverse ABCB1-mediated tumor multidrug resistance and improve the drug resistance of the ABCB1-mediated tumor, so that the drug resistance of the ABCB1-mediated tumor is reduced, and the drug resistance of the ABCB1-mediated tumor is improved. Therefore, the treatment of the ABCB1 mediated multidrug resistance tumor is realized by combining the ABCB1 substrate and chemotherapy drugs. 本发明属于生物医药技术领域，涉及多药耐药性肿瘤的治疗，具体涉及falnidamol在逆转肿瘤多药耐药中的应用。本发明经过研究发现，falnidamol作为一种高效的ABCB1蛋白抑制剂，可通过与ABCB1蛋白的底物结合位点相互作用，抑制ABCB1蛋白的化疗药物外排功能，